Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase II, prospective, randomized, open-label study to evaluate the immune responses of FluMist compared with trivalent inactivated vaccine (TIV) in children 12 to less than 36 months of age

Next Previous
X
Search
Trial Profile

A phase II, prospective, randomized, open-label study to evaluate the immune responses of FluMist compared with trivalent inactivated vaccine (TIV) in children 12 to less than 36 months of age

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 10 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Influenza virus vaccine live (Primary) ; Influenza virus vaccine
  • Indications Influenza A virus H1N1 subtype; Influenza B virus infections; Influenza virus infections
  • Focus Pharmacodynamics; Pharmacogenomic
  • Sponsors MedImmune

    • Most Recent Events

    • 04 May 2010 Results of transcriptional analysis were presented at the Annual Meeting of the Pediatric Academic Societies 2010.
    • 09 Feb 2010 Actual number of patients (101) added as reported by ClinicalTrials.gov record
    • 01 Nov 2009 Results reported at 47th Annual IDSA meeting, according to MedImmune media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top